[1]武敏,艾文婷,李小凤,等.补肾健骨胶囊对绝经后骨质疏松患者骨代谢相关指标的影响[J].现代检验医学杂志,2015,30(05):73-75.[doi:10.3969/j.issn.1671-7414.2015.05.022]
 WU min,AI Wen-ting,LI Xiao-feng,et al.Change of Bone Metabolism in Postmenopausal Osteoporosis Patients Treated with Bushenjiangu Capsule[J].Journal of Modern Laboratory Medicine,2015,30(05):73-75.[doi:10.3969/j.issn.1671-7414.2015.05.022]
点击复制

补肾健骨胶囊对绝经后骨质疏松患者骨代谢相关指标的影响()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
73-75
栏目:
论著
出版日期:
2015-12-10

文章信息/Info

Title:
Change of Bone Metabolism in Postmenopausal Osteoporosis Patients Treated with Bushenjiangu Capsule
作者:
武敏艾文婷李小凤王养维
陕西省人民医院,西安710068
Author(s):
WU minAI Wen-tingLI Xiao-fengWANG Yang-wei
Shaanxi Provincial People’s Hospital,Xi’an 710068,China
关键词:
骨质疏松绝经期补肾健骨胶囊骨代谢炎性因子
分类号:
R591.1;R392.11
DOI:
10.3969/j.issn.1671-7414.2015.05.022
文献标志码:
A
摘要:
目的观察补肾健骨胶囊对绝经后骨质疏松症炎性因子和骨代谢指标的影响。方法106例绝经后骨质疏松症患者随机分为两组,试验组服用补肾健骨胶囊,对照组服用钙尔奇D,6个月后检测血清中肿瘤坏死因子-α(TNF-α),白介素-6(IL-6),骨碱性磷酸酶(BLAP),骨钙蛋白(BGP),骨保护素(OPG),血浆抗酒石酸盐酸性磷酸酶(TRAP)和骨密度水平。结果用药前试验组和对照组年龄,骨代谢指标和炎性因子水平间差异无统计学意义(P<0.05)。与用药前比较,试验组用药后血清IL-6和TNF-α水平显著下降,差异具有统计学意义(P<0.01),而对照组用药后变化不明显(P<0.05); 与对照组用药后比较,试验组用药后IL-6和TNF-α值降低,差异有统计学意义(P>0.05)。试验组和对照组用药后BLAP,BGP,OPG和骨密度检测值较用药前升高,TRAP水平降低,差异均有统计学意义(P>0.05);较对照组用药后,试验组OPG水平升高明显,差异具有统计学意义(P<0.05),余骨代谢指标和骨密度两组间差异不明显(P>0.05)。结论补肾健骨胶囊可改善绝经后骨质疏松患者骨代谢异常,在抑制炎性因子发生和提升OPG水平方面作用优于传统钙剂。
Abstract:
ObjectiveTo investigate the effective of Bushenjiangu Capsule on bone metabolism and inflammatory cytokines in postmenopausal osteoporosis (PMOP).Methods106 PMOP patients was randomly divided into two groups,the experimental group taken Bushenjiangu Capsule,and control group taken Caltrate.ResultsThere was no difference in year,bone metabolism and inflammatory cytokines.Inflammatory cytokines of the experimental group had a significant decrease after treatment (P<0.01).In two group after treatment,the level of BLAP,BGP,OPG and BMD were increased (P>0.05),TRAP was fallen (P<0.05).The OPG level of experimental group was higher than the control group after treated (P>0.05).ConclusionBushenjiangu Capsule can improve bone metabolic abnormalities in patients with postmenopausal osteoporosis.

参考文献/References:

[1]中国健康促进基金会骨质疏松防治中国白皮书编委会.骨质疏松症中国白皮书[J].中华健康管理学杂志,2009,3(3):148-154. Editorial Board of Osteoporosis Prevention and Treatment(China White Pager).China Health Prmotron Foundation White Paper on Osteoporosis[J].Chinese Journal of Health Management,2009,3(3):148-154.
[2]马伟,牟慧琴,马占洋.绝经后骨质疏松症中医病因病机研究概况[J].中医杂志,2012,53(13):1152-1154. Ma W,Mo HQ,Ma ZY.[J].Journal of Traditional Chinese Medicine,2012,53(13):1152-1154.
[3]丁桂芝,张忠兰,周勇,等.补肾健骨胶囊治疗绝经后骨质疏松症疗效分析[J].中国中西医结合杂志,1995,15(7):392-394. Ding GZ,Zhang ZL,Zhou Y,et al.Clinical study on effect of bushen jiangu capsule on postmenopusal osteoporosis[J].Chinese Journal of Integrated Traditional and Western Medicine,1995,15(7):392-394.
[4]Kotake S,Nanke Y.Effect of TNF-α on osteoblastogenesis from mesenchymal stem cells[J].Biochimicaet Biophysica Acta,2014,1840(3):1209-1213.
[5]Briolaya A,Lencelb P,Bessueillea L,et al.Autocrine stimulation of osteoblast activity by Wnt5a in response to TNF-α in human mesenchymal stem cells[J].Biochemical and Biophysical Research Communications,2013,430(3):1072-1077.
[6]钱兴皋,刘宇恒,王琴,等.炎症因子对骨质疏松症发病影响的研究进展[J].中国康复理论与实践,2013,19(7):645-646. Qian XG,Liu YH,Wang Q,et al.Inflammatory factors and pathogenesis of osteoporpsis(review)[J].Chin J Rehabil Theory Pract,2013,19(7):645-646.
[7]张萌萌.中国老年学学会骨质疏松委员会骨代谢生化指标临床应用专家共识[J]. 中国骨质疏松杂志,2014,20(11):1263-1269. Zhang MM.Expert consensus of clinical application of the bone metabolic and biochemical markers,by osteoporosis committee in Chinese gerontological society[J].Chinese Journal of Osteoporosis,2014,20(11):1263-1269.
[8]丁仁,尹宏,钱卫庆,等.骨保护素在预测和治疗绝经后骨质疏松症中的应用[J].国际骨科杂志,2011,32(1):24-26. Ding R,Yin H,Qian WQ,et al.[J].Int J Orthop,2011,32(1):24-26. 收稿日期:2015-06-19修回日期:2015-07-01(上接72页)2015,24(9):1013-1016. Sun J,Zhao YH,Zhou J.Basic theory the therapy CBF-AML with dasatinib and the advance in clinical study[J].Chinese Journal of New Drugs,2015,24(9):1013-1016.
[11]王杨,于淼.石蒜碱诱导人白血病K562细胞凋亡的研究[J].哈尔滨商业大学学报(自然科学版),2015,31(2):135-139,169. Wang Y,Yu M.Study on lycorine-induced apoptosis of human K562 cells[J].Journal of Harbin University of Commerce(Natural Science Edition),2015,31(2):135-139,169.
[12]丁亦含,樊晓东,吴晶晶,等.Survivin抑制剂YM155对K562细胞凋亡和自噬的影响[J].中国实验血液学杂志,2015,23(2):375-380. Ding YH,Fan XD,Wu JJ,et al.Effect of YM155 on apoptosis and autophagy of K562 cells[J].Journal of Experimental Hematology,2015,23(2):375-380.
[13]邱林,王晓丹,于波海,等.新型酪氨酸激酶抑制剂HHGV 678对Bcr-Ab野生型细胞株和伊马替尼耐药细胞株抑制作用的体外研究[J].中国实验血液学杂志,2008,16(5):1039-1043. Qiu L,Wang XD,Yu BH,et al.Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr-Ab wild type and IM-resistant cell lines in vitro[J].Journal of Experimental Hematology,2008,16(5):1039-1043.

相似文献/References:

[1]周 萍,郭 璇,武 倩,等.西安地区更年期女性骨代谢指标预测骨质疏松效果评估[J].现代检验医学杂志,2017,32(02):149.[doi:10.3969/j.issn.1671-7414.2017.02.042]
 ZHOU Ping,GUO Xuan,WU Qian,et al.Evaluation of Boned Metabolism Quota in the Prediction of Osteoporosis of Climacteric Female in Xi'an Area[J].Journal of Modern Laboratory Medicine,2017,32(05):149.[doi:10.3969/j.issn.1671-7414.2017.02.042]
[2]廖 强,王 娟.骨质疏松患者血清25(OH)D,骨膜素、铁蛋白水平及其与骨折发生的相关性分析[J].现代检验医学杂志,2021,36(05):138.[doi:10.3969/j.issn.1671-7414.2021.05.031]
 LIAO Qiang,WANG Juan.Serum Levels of 25(OH)D, Periostin and Ferritin in Patients with Osteoporosisand Their Correlation with Fracture[J].Journal of Modern Laboratory Medicine,2021,36(05):138.[doi:10.3969/j.issn.1671-7414.2021.05.031]

备注/Memo

备注/Memo:
基金项目: 陕西省社发攻关项目(NO.2006K14-G1)。 作者简介:武敏(1978-),女,硕士,主治医生,专业:内分泌疾病。
更新日期/Last Update: 1900-01-01